# Guang Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8640805/publications.pdf

Version: 2024-02-01

| 77 | 6,196 | 156536 | 78623 |
|---|---|---|---|
| papers | citations | 32 h-index | 77 g-index |

| 81 | 81 | 81 | 5281 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171. | 1.7 | 11 |
| 2 | Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539. | 3.3 | 50 |
| 3 | Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71. | 0.8 | 53 |
| 4 | A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338. | 2.5 | 4 |
| 5 | Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550. | 1.2 | 8 |
| 6 | Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575. | 0.8 | 98 |
| 7 | Coronavirus diseases 2019 and kidney injury: a brief review based on current evidence. Chinese Medical Journal, 2021, 134, 993-995. | 0.9 | 0 |
| 8 | Epigenetic targeting of WaldenstrÃ¶m macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics, 2021, 13, 129-144. | 1.0 | 7 |
| 9 | Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733. | 1.2 | 16 |
| 10 | Cellâ€free <scp>DNA</scp> analysis for detection of <scp>MYD88<sup>L265P</sup></scp> and <scp>CXCR4<sup>S338X</sup></scp> mutations in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253. | 2.0 | 8 |
| 11 | The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979. | 0.6 | 16 |
| 12 | Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated WaldenstrÃ¶m macroglobulinemia. Blood, 2021, 138, 1535-1539. | 0.6 | 32 |
| 13 | Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624. | 1.2 | 15 |
| 14 | The clinical and genetic research of Waardenburg syndrome type I and II in Chinese families. International Journal of Pediatric Otorhinolaryngology, 2020, 130, 109806. | 0.4 | 5 |
| 15 | Comparative genomics of CXCR4MUT and CXCR4WT single cells in WaldenstrÃ¶mâ€™s macroglobulinemia. Blood Advances, 2020, 4, 4550-4553. | 2.5 | 3 |
| 16 | Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363. | 1.2 | 12 |
| 17 | Ixazomib, dexamethasone, and rituximab in treatment-naive patients with WaldenstrÃ¶m macroglobulinemia: long-term follow-up. Blood Advances, 2020, 4, 3952-3959. | 2.5 | 35 |
| 18 | Meta-analysis of association between CT-based features and tumor spread through air spaces in lung adenocarcinoma. Journal of Cardiothoracic Surgery, 2020, 15, 243. | 0.4 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19â€“infected patients. Blood, 2020, 135, 1912-1915. | 0.6 | 253 |
| 20 | Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208. | 0.8 | 103 |
| 21 | Genomic evolution of ibrutinibâ€resistant clones in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2020, 189, 1165-1170. | 1.2 | 23 |
| 22 | <scp>CXCR4</scp> mutational status does not impact outcomes in patients with <scp>W</scp>aldenstrÃ¶m macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98. | 2.0 | 12 |
| 23 | A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394. | 0.6 | 9 |
| 24 | SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal, 2020, 10, 12. | 2.8 | 34 |
| 25 | Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Advances, 2020, 4, 141-153. | 2.5 | 13 |
| 26 | CXCR4 mutation subtypes impact response and survival outcomes in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363. | 1.2 | 73 |
| 27 | Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell Lung Cancers: a Meta-Analysis Including 3564 Patients. Pathology and Oncology Research, 2019, 25, 1303-1310. | 0.9 | 43 |
| 28 | Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Advances, 2019, 3, 3360-3374. | 2.5 | 25 |
| 29 | CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2019, 3, 2800-2803. | 2.5 | 27 |
| 30 | Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802. | 1.2 | 4 |
| 31 | Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 1011-1014. | 1.2 | 19 |
| 32 | Response and survival for primary therapy combination regimens and maintenance rituximab in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 77-85. | 1.2 | 41 |
| 33 | BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood, 2018, 131, 2047-2059. | 0.6 | 61 |
| 34 | Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2018, 24, 3247-3252. | 3.2 | 57 |
| 35 | MYD88 mutated and wild-type WaldenstrÃ¶mâ€™s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica, 2018, 103, e408-e411. | 1.7 | 30 |
| 36 | <scp>MYD</scp>88 wildâ€type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andÂoverall survival. British Journal of Haematology, 2018, 180, 374-380. | 1.2 | 83 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761. | 0.8 | 142 |
| 38 | Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 745-752. | 0.9 | 16 |
| 39 | A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. Blood, 2018, 132, 40-40. | 0.6 | 9 |
| 40 | Insights into the genomic landscape of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 2937-2946. | 2.5 | 72 |
| 41 | Acquired mutations associated with ibrutinib resistance in WaldenstrÃ¶m macroglobulinemia. Blood, 2017, 129, 2519-2525. | 0.6 | 115 |
| 42 | Serum IgM level as predictor of symptomatic hyperviscosity in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725. | 1.2 | 58 |
| 43 | Novel approaches to targeting MYD88 in WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2017, 10, 739-744. | 1.0 | 6 |
| 44 | CXCL13 levels are elevated in patients with WaldenstrÃ¶m macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455. | 1.7 | 22 |
| 45 | Idelalisib in WaldenstrÃ¶m macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004. | 0.6 | 31 |
| 46 | Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404. | 3.2 | 23 |
| 47 | Genomics, Signaling, and Treatment of WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2017, 35, 994-1001. | 0.8 | 76 |
| 48 | Transcriptome sequencing reveals a profile that corresponds to genomic variants in WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 128, 827-838. | 0.6 | 91 |
| 49 | Future therapeutic options for patients with WaldenstrÃ¶m macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 206-215. | 0.7 | 4 |
| 50 | HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood, 2016, 127, 3237-3252. | 0.6 | 93 |
| 51 | Mechanisms Underlying Footshock and Psychological Stress-Induced Abrupt Awakening From Posttraumatic â€œNightmaresâ€• International Journal of Neuropsychopharmacology, 2016, 19, pyv113. | 1.0 | 13 |
| 52 | Clonal architecture of <scp>CXCR</scp>4 <scp>WHIM</scp>â€like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744. | 1.2 | 122 |
| 53 | The <scp>BCL</scp>2 antagonist <scp>ABT</scp>â€199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <scp>CXCR</scp>4<sup>Wildâ€type</sup> and <scp>CXCR</scp>4<scp><sup>WHIM</sup></scp> mutated Waldenstrom macroglobulinaemia cells. British Journal of Haematology, 2015, 170, 134-138. | 1.2 | 63 |
| 54 | Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2015, 21, 2538-2545. | 3.2 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A novel mutation of EYA4 in a large Chinese family with autosomal dominant middle-frequency sensorineural hearing loss by targeted exome sequencing. Journal of Human Genetics, 2015, 60, 299-304. | 1.1 | 16 |
| 56 | Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440. | 13.9 | 810 |
| 57 | <scp>CXCR</scp>4 <scp>WHIM</scp>â€like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant <scp>MYD</scp>88<sup>L265P</sup>â€directed survival signalling in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia cells. British Journal of Haematology, 2015, 168, 701-707. | 1.2 | 95 |
| 58 | The genomic landscape of WaldenstrÃ¶m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 2014, 123, 1637-1646. | 0.6 | 394 |
| 59 | Proteomic analysis on infantile spasm and prenatal stress. Epilepsy Research, 2014, 108, 1174-1183. | 0.8 | 2 |
| 60 | Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2791-2796. | 0.6 | 337 |
| 61 | Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating WaldenstrÃ¶m's macroglobulinemia. Blood, 2014, 124, 503-510. | 0.6 | 168 |
| 62 | Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2. Blood, 2014, 124, 4714-4714. | 0.6 | 0 |
| 63 | MYD88 L265P in WaldenstrÃ¶m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood, 2013, 121, 2051-2058. | 0.6 | 368 |
| 64 | A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 122, 1222-1232. | 0.6 | 306 |
| 65 | Bone Marrow Microenvironment Affects The Pathogenesis Of Multiple Myeloma Through Downregulation Of Alternative Splicing Factor Fox2 In Myeloma Cells. Blood, 2013, 122, 3085-3085. | 0.6 | 1 |
| 66 | Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 757-757. | 0.6 | 6 |
| 67 | Sp1 Inhibition Affects Cell Growth and Survival In Waldenstromâ€™s Macroglobulinemia Through a MYD88-Independent Pathway. Blood, 2013, 122, 3065-3065. | 0.6 | 0 |
| 68 | MYD88 L265P Somatic Mutation in WaldenstrÃ¶m's Macroglobulinemia. New England Journal of Medicine, 2012, 367, 826-833. | 13.9 | 1,142 |
| 69 | Whole Genome Sequencing Identifies Recurring Somatic Mutations in the C-Terminal Domain of CXCR4, Including a Gain of Function Mutation in Waldenstrom's Macroglobinemia.. Blood, 2012, 120, 2715-2715. | 0.6 | 1 |
| 70 | MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase. Blood, 2012, 120, 897-897. | 0.6 | 1 |
| 71 | Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 152-156. | 0.2 | 22 |
| 72 | Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis. Cancer Research, 2009, 69, 9029-9037. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Inhibition of PAX3 by TGF-Î² Modulates Melanocyte Viability. Molecular Cell, 2008, 32, 554-563. | 4.5 | 121 |
| 74 | Loss of Xeroderma Pigmentosum C (Xpc) Enhances Melanoma Photocarcinogenesis in Ink4a-Arfâ€“Deficient Mice. Cancer Research, 2007, 67, 5649-5657. | 0.4 | 40 |
| 75 | Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. Journal of Investigative Dermatology, 2006, 126, 2490-2506. | 0.3 | 86 |
| 76 | High-dose chemotherapy with autologous peripheral blood stem cell support in children with malignant diseases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2005, 17, 288-290. | 0.7 | 1 |
| 77 | A Novel Methionine-53-Valine Mutation of p16 in a Hereditary Melanoma Kindred. Journal of Investigative Dermatology, 2004, 123, 574-575. | 0.3 | 8 |